Heat Biologics Appoints Paul Tebbey as Senior Vice President of Product Development and Portfolio Strategy
06 oct. 2021 07h30 HE
|
Heat Biologics
DURHAM, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...
Heat Biologics CEO to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29th
15 sept. 2021 07h30 HE
|
Heat Biologics
DURHAM, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...
Heat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
09 sept. 2021 08h30 HE
|
Heat Biologics
DURHAM, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...
Heat Biologics to Provide Corporate Update
30 août 2021 07h30 HE
|
Heat Biologics
DURHAM, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...
Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary
26 août 2021 08h00 HE
|
Heat Biologics
DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...
Heat Biologics Announces Addition of Former US Senator Mark Pryor to Biothreat Advisory Board
23 août 2021 08h00 HE
|
Heat Biologics
DURHAM, N.C., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...
Heat Biologics Announces New Additions to Biothreat Advisory Board
19 août 2021 09h00 HE
|
Heat Biologics
Former Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs, Andrew C. Weber Expert on Chemical and Biological Weapons, Dr. Gregory Koblentz DURHAM, N.C., Aug. 19,...
Heat Biologics Announces Formation of Biothreat Advisory Board
18 août 2021 08h00 HE
|
Heat Biologics
DURHAM, N.C., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...
Heat Biologics Provides Second Quarter 2021 Business Update
11 août 2021 16h05 HE
|
Heat Biologics
DURHAM, N.C., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the...
Heat Biologics Announces Groundbreaking for New San Antonio Facility
09 août 2021 07h30 HE
|
Heat Biologics
DURHAM, N.C., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...